Calidi Biotherapeutics公司宣布，其候选疗法Cld-401已获得美国食品药品监督管理局（FDA）积极的Pre-IND（研究性新药申请前）会议反馈。这一进展标志着监管机构与公司就Cld-401当前的整体开发策略达成共识，为推进该疗法进入首次人体临床研究扫清了关键路径。公司正基于此反馈，积极准备后续的IND申请工作。
Calidi Biotherapeutics公司宣布，其候选疗法Cld-401已获得美国食品药品监督管理局（FDA）积极的Pre-IND（研究性新药申请前）会议反馈。这一进展标志着监管机构与公司就Cld-401当前的整体开发策略达成共识，为推进该疗法进入首次人体临床研究扫清了关键路径。公司正基于此反馈，积极准备后续的IND申请工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.